Clinical Trial: Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07690943) titled 'Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients' on June 30.

Brief Summary: The goal of this clinical study is to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell (LB-DTK-COV19) treatment in prolonged SARS-CoV-2 infected patients. The main questions it aims to answer are:

* What adverse events occur after the infusion of LB-DTK-COV19?

* Is there a clinically significant improvement in clinical symptoms within 4 weeks after the infusion?

* Is there a clinically significant reduction in SARS-CoV-2 viral load within 4 weeks after the ...